HER2-negative breast cancer represents the majority of breast cancer cases, accounting for about 80% of diagnoses. Understanding how this form of cancer responds to treatment and what new therapies are being explored can help patients and their families navigate the path ahead with greater confidence and clarity.

Understanding Treatment Goals and Approaches

When someone receives a diagnosis of HER2-negative breast cancer, the main goal of treatment is to control the disease, improve quality of life, and prevent the cancer from spreading. The treatment plan depends heavily on the specific characteristics of the cancer cells, the stage of the disease when it’s discovered, and the individual patient’s overall health condition. Some patients may need treatment to remove the cancer completely, while others may focus on managing symptoms and slowing the disease’s progression.^[1]

HER2-negative breast cancer is a type where cancer cells don’t have high levels of a protein called human epidermal growth factor receptor 2, or HER2 for short. This protein normally helps breast cells grow and repair themselves. When there’s too much of it, cancer can become more aggressive. But in HER2-negative cases, this protein isn’t driving the cancer’s growth, so treatments that target HER2 won’t be effective.^[2]

Understanding that HER2-negative breast cancer isn’t just one disease is important. It actually includes two main subtypes. The most common type is hormone receptor positive (HR+/HER2-), which makes up about 70% of all breast cancers. In this type, hormones like estrogen or progesterone fuel the cancer’s growth. The second type is called triple-negative breast cancer (HR-/HER2-), which accounts for about 11% of cases. This form doesn’t respond to hormones or HER2, making it more challenging to treat because it doesn’t have these specific targets.^[1]

Medical societies have developed standard treatment guidelines based on years of research and clinical experience. These guidelines help doctors choose the best proven therapies for each patient’s situation. At the same time, researchers are constantly working on new treatments through clinical trials, which are carefully designed studies that test promising therapies before they become widely available. Patients may have the opportunity to participate in these trials, gaining access to innovative treatments while contributing to medical progress.^[4]

Standard Treatment Options

The standard treatment for HER2-negative breast cancer typically involves a combination of approaches, tailored to whether the cancer is hormone receptor positive or triple-negative. For most patients with hormone receptor positive disease, doctors start with hormone therapy because it tends to have fewer serious side effects compared to chemotherapy and can effectively slow or stop cancer growth.^[11]

Hormone therapy works by blocking the effects of estrogen and progesterone on cancer cells or by lowering the body’s production of these hormones. Several types of hormone therapy drugs are commonly used. Aromatase inhibitors like anastrozole (Arimidex), exemestane (Aromasin), and letrozole (Femara) reduce estrogen levels in the body, particularly in women who have gone through menopause. Another drug called fulvestrant (Faslodex) works differently by destroying estrogen receptors on cancer cells. Tamoxifen is another important hormone therapy that blocks estrogen from attaching to cancer cells. These medications can be taken as pills or given as injections, making them relatively convenient for long-term use.^[11]

Chemotherapy remains an important treatment option, especially for triple-negative breast cancer and for some cases of hormone receptor positive disease where the cancer is more aggressive or hasn’t responded well to hormone therapy. Chemotherapy uses powerful drugs to kill rapidly dividing cancer cells throughout the body. Doctors may use different types of chemotherapy drugs, either alone or in combinations. Common categories include taxanes and anthracyclines, which work by interfering with cancer cells’ ability to divide and multiply.^[11]

Chemotherapy is usually given in cycles, with treatment periods followed by rest periods to allow the body to recover. Each cycle typically lasts two to three weeks. While chemotherapy can be very effective at destroying cancer cells, it also affects healthy cells that divide quickly, leading to side effects. Patients may experience fatigue, nausea, hair loss, increased risk of infection, and changes in appetite. However, doctors have many supportive medications available to help manage these side effects and maintain quality of life during treatment.^[11]

Surgery is often part of the treatment plan, particularly for early-stage disease. Doctors may perform a lumpectomy, which removes just the tumor and a small amount of surrounding tissue, or a mastectomy, which removes the entire breast. The choice depends on the tumor’s size and location, the patient’s preference, and other factors. In many cases, surgery is combined with radiation therapy to ensure any remaining cancer cells in the area are destroyed.^[4]

Radiation therapy uses high-energy beams to kill cancer cells in a specific area. It’s commonly used after surgery to reduce the risk of cancer returning in the breast or nearby lymph nodes. Treatment typically involves daily sessions over several weeks, with each session lasting just a few minutes. While radiation therapy is generally well-tolerated, it can cause skin changes in the treated area, similar to a sunburn, and may lead to fatigue.^[4]

Targeted therapy represents a more precise approach that focuses on specific molecules involved in cancer growth. For HER2-negative breast cancer, certain targeted therapies are available. PARP inhibitors like olaparib (Lynparza) and talazoparib (Talzenna) are used for patients who have inherited mutations in the BRCA1 or BRCA2 genes. These drugs prevent cancer cells from repairing their damaged DNA, causing the cells to die. PARP inhibitors have shown particular promise in treating both hormone receptor positive and triple-negative breast cancer in patients with BRCA mutations.^[11]

Another targeted therapy called capivasertib (Truqap) blocks a protein pathway called AKT, which helps cancer cells survive and grow. This drug is used in combination with hormone therapy for patients whose cancer has specific genetic characteristics. The duration of standard treatment varies widely. Some patients may complete treatment within several months, while others, particularly those with hormone receptor positive disease, may continue hormone therapy for five to ten years to reduce the risk of recurrence.^[11]

Innovative Treatments in Clinical Trials

While standard treatments have helped many patients, researchers continue to develop new therapies that may offer better outcomes with fewer side effects. Clinical trials test these promising approaches before they become widely available. Understanding what’s being studied can help patients make informed decisions about whether to participate in research studies.^[13]

One major area of investigation focuses on the PI3K/AKT signaling pathway, a complex system of proteins that controls cell growth and survival. In many breast cancers, this pathway becomes overactive, causing cells to multiply uncontrollably. Researchers are testing several types of drugs that block different parts of this pathway. PI3K inhibitors stop the PI3K protein from sending growth signals to cancer cells. AKT inhibitors target the AKT protein, which sits downstream in the signaling pathway. mTOR inhibitors block the mTOR protein, which also plays a role in cell growth and metabolism.^[13]

These inhibitors work by interfering with the cancer cell’s ability to receive and process signals that tell it to grow and divide. When these signals are blocked, cancer cells may stop growing or even die. Clinical trials are testing these drugs alone and in combination with hormone therapy to see if they can improve outcomes for patients with HER2-negative breast cancer. Early results have been encouraging, with some studies showing that these drugs can slow disease progression, particularly in patients whose cancer has become resistant to standard hormone therapy.^[13]

CDK inhibitors represent another class of targeted therapy being studied extensively. CDK stands for cyclin-dependent kinases, which are proteins that control the cell cycle, the process by which cells divide and multiply. When CDK proteins are overactive, cells divide too rapidly, leading to cancer growth. CDK inhibitors work by putting the brakes on this process, preventing cancer cells from dividing. Several CDK inhibitors have shown promise in clinical trials for hormone receptor positive HER2-negative breast cancer, both in early-phase studies testing safety and in later-phase studies comparing them to standard treatments.^[13]

Aurora kinase inhibitors are another type of cell cycle inhibitor being explored in clinical trials. Aurora kinases are proteins that help cells divide properly. When these proteins don’t work correctly, cells can divide abnormally, leading to cancer. Inhibitors of aurora kinases prevent cancer cells from completing cell division, causing them to die. These drugs are being tested in Phase I and Phase II trials to determine their safety and effectiveness in patients with HER2-negative breast cancer.^[13]

Researchers are also investigating ways to starve tumors by blocking their blood supply. Cancer tumors need a constant supply of blood to bring nutrients and oxygen. Angiogenesis inhibitors are drugs that prevent tumors from forming new blood vessels. These small molecule tyrosine kinase inhibitors target proteins that signal blood vessels to grow toward the tumor. By cutting off the tumor’s blood supply, these drugs can slow or stop cancer growth. Clinical trials are testing various angiogenesis inhibitors to see if they can improve outcomes when combined with standard chemotherapy or hormone therapy.^[13]

Immunotherapy is an exciting area of research that harnesses the body’s own immune system to fight cancer. The immune system normally recognizes and destroys abnormal cells, but cancer cells can sometimes hide from immune detection. Immunotherapy drugs help the immune system recognize and attack cancer cells. For HER2-negative breast cancer, particularly triple-negative disease, researchers are testing drugs called checkpoint inhibitors that remove the brakes on the immune system, allowing it to attack cancer more effectively. Some clinical trials have shown that immunotherapy, when combined with chemotherapy, can improve outcomes for patients with advanced triple-negative breast cancer.^[4]

HDAC inhibitors represent yet another approach being explored in clinical trials. HDAC stands for histone deacetylase, an enzyme that affects how genes are expressed in cells. By blocking HDAC, these drugs can change which genes are turned on or off in cancer cells, potentially causing them to stop growing or die. HDAC inhibitors are being tested both alone and in combination with other treatments to see if they can improve outcomes for patients with HER2-negative breast cancer.^[13]

Research into breast cancer stem cells is opening new avenues for treatment. These are special cancer cells that can self-renew and give rise to all the other cells in a tumor. They’re thought to be responsible for cancer recurrence after treatment. Scientists are working on therapies that specifically target these stem cells, with the hope of preventing cancer from coming back. These treatments are still in early-phase clinical trials, but they represent a promising approach for the future.^[13]

A particularly important recent development involves HER2-low breast cancer. Scientists have discovered that some cancers previously classified as HER2-negative actually have small amounts of HER2 protein on their surface. These are now called HER2-low cancers. New drugs called antibody-drug conjugates can target even these low levels of HER2, delivering chemotherapy directly to cancer cells. Clinical trials testing these drugs in HER2-low patients have shown promising results, offering hope to patients whose cancers don’t have enough HER2 to respond to traditional HER2-targeted therapies but have just enough to be targeted by these newer, more sensitive drugs.^[14]

Many clinical trials are actively recruiting patients with HER2-negative breast cancer. Eligibility typically depends on factors like the stage of cancer, previous treatments received, genetic characteristics of the tumor, and the patient’s overall health. Patients interested in clinical trials should discuss this option with their oncologist, who can help determine which trials might be appropriate and explain the potential risks and benefits of participation.^[4]

Most Common Treatment Methods

• Hormone Therapy
  • Aromatase inhibitors (anastrozole, exemestane, letrozole) that reduce estrogen production in the body, particularly useful for postmenopausal women with hormone receptor positive disease
  • Fulvestrant (Faslodex), which destroys estrogen receptors on cancer cells and can be given as an injection
  • Tamoxifen (Nolvadex, Soltamox), which blocks estrogen from attaching to cancer cells and can be taken as a pill
  • Drugs like goserelin (Zoladex) and leuprolide (Lupron) that stop the body from making estrogen, sometimes used with other hormone therapies
• Chemotherapy
  • Taxanes and anthracyclines, categories of chemotherapy drugs often used to treat HER2-negative breast cancer, particularly triple-negative disease
  • Treatment given in cycles of 2 to 3 weeks, with rest periods between cycles to allow the body to recover from drug effects
  • Can be administered as pills or through an IV, depending on the specific drugs used
• Targeted Therapy
  • PARP inhibitors (olaparib/Lynparza and talazoparib/Talzenna) for patients with BRCA gene mutations, which prevent cancer cells from repairing their damaged DNA
  • Capivasertib (Truqap), which blocks the AKT protein pathway and is used with hormone therapy for patients with specific genetic characteristics
  • PI3K inhibitors, AKT inhibitors, and mTOR inhibitors being tested in clinical trials to block the PI3K/AKT signaling pathway
  • CDK inhibitors that control the cell cycle and prevent cancer cells from dividing too rapidly
• Immunotherapy
  • Checkpoint inhibitors that help the immune system recognize and attack cancer cells, particularly useful for triple-negative breast cancer
  • Usually combined with chemotherapy to improve outcomes for patients with advanced disease
• Surgery
  • Lumpectomy, which removes just the tumor and a small amount of surrounding tissue while preserving most of the breast
  • Mastectomy, which removes the entire breast and may be recommended depending on tumor size, location, and patient preference
  • Often combined with radiation therapy to ensure any remaining cancer cells are destroyed
• Radiation Therapy
  • Uses high-energy beams to kill cancer cells in a specific area after surgery
  • Typically involves daily sessions over several weeks, with each session lasting just a few minutes
  • Commonly used to reduce the risk of cancer returning in the breast or nearby lymph nodes